Genomics, Biotech, and Emerging Medical Technologies
Biologic agents have revolutionized the treatment of many diseases, including breast cancer, lung cancer, non-Hodgkin’s lymphoma, hepatitis, inflammatory bowel disease (IBD), rheumatoid arthritis, and many more. Biosimilars are expected to have a significant impact on healthcare but present a unique set of challenges for regulators, clinicians, payers, and consumers. The development of new biologics may be a big step in effectively treating diseases for which there are currently no cures. At present, there are biosimilars for filgrastim, infliximab, etanercept, adalimumab, trastuzumab, and bevacizumab. The FDA looks at biosimilars as a biological product that is similar to a U.S. licensed biological product not including minor differences in clinically inactive components, as well as having no clinically meaningful differences between the biological product and the reference product in terms of the safety, efficacy and potency of the product. Recent and upcoming patent expirations for some of the most commonly used biologic agents have led to the development of biosimilar products. Evidence suggests that clinicians need to be continually educated about the multiple aspects of biosimilars, including the underlying scientific principles, the development and regulatory pathways, how to use them in clinical practice, as well as educating their patients about their value.
To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.
For more information contact Jeremy Williams at 804-527-1905 or firstname.lastname@example.org.
NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.